Navigation Links
Biotechnology Thought Leader, Dr. Abbie Celniker, Joins ImaginAb Board of Directors as Chairman

LOS ANGELES and BOSTON, Aug. 13, 2012 /PRNewswire/ -- ImaginAb, Inc. a developer of in vivo molecular imaging agents based on its proprietary antibody fragment platform, today announced that Abbie Celniker, Ph.D. has joined the company as a Director and Chair of the Board.

"In ImaginAb's search for Board leadership, we set out to attract an industry visionary with perspective from big biopharma as well as entrepreneurial experience and we have found all of these qualities in Dr. Celniker." said Christian Behrenbruch, Ph.D., Chief Executive Officer of ImaginAb. "We are delighted to welcome Dr. Celniker to our team and look forward to her contributions as we develop our groundbreaking in vivo molecular imaging agents."

"Companion diagnostic strategies are increasingly critical to new therapeutic management strategies in the oncology and immunology space," commented Dr. Celniker. "ImaginAb's platform for re-engineering therapeutic antibody drugs into imaging agents is unique in the industry and bears great potential. ImaginAb is beginning to realize the promise of this technology by advancing its internal clinical pipeline in cancer and autoimmune diseases, as well as multiple collaborations with biopharma."

Abbie Celniker, Ph.D., is currently President and CEO of Eleven Biotherapeutics (Boston, MA) and brings more than 20 years of proven expertise in building protein discovery and development programs and biologics-focused businesses. Prior to Eleven Biotherapeutics, she led Taligen, which was acquired by Alexion Pharmaceuticals in 2011. Dr. Celniker was formerly the global head of biologics at Novartis, where she forged strategic alliances and led internal discovery and development to build the pipeline. Earlier in her career, Dr. Celniker spent more than six years at Millennium Pharmaceuticals as senior vice president, R&D strategy and operations and head of biotherapeutics and pharmaceutical sciences. She also held development roles with Wyeth BioPharma (Genetics Institute) and Genentech.

About ImaginAb
ImaginAb is redefining therapeutic management by harnessing the power of antibody technology for in vivo imaging. The company's proprietary antibody fragment platform yields actionable molecular information to guide treatment decisions in cancer and immunology. ImaginAb also collaborates with select biopharmaceutical partners to design imaging agents as companion diagnostics for therapeutic antibodies. ImaginAb's technology is positioned to deliver on the promise of personalized medicine by improving patient outcomes and reducing the cost of healthcare.

For more information, visit

SOURCE ImaginAb, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
2. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
3. TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin, to Zhejiang Medicine
4. Antibiotics and Biotechnology Take Center Stage at Food Dialogues Event
5. Next Generation Pharmaceutical Manufacturing Summit Pushes the Envelope of Thought-Leadership at its September Summit in London
6. TMG Health To Present Kip Piper at Thought Leadership Dinner
7. GDS Internationals Fourth Next Generation Pharmaceutical Drug Development Summit Attracts an Unprecedented Delegation of Thought Leaders
8. Nutrilys Del Mar Joins Health Forces With LAPD Underwater Dive Unit
9. Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
10. Aethlon Medical Note: Marc Robins Joins the Aethlon Team
11. Effie Toshav Joins Fenwick - Broadens Life Sciences Service Platform
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
Breaking Medicine News(10 mins):